Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07335614 · ClinicalTrials.gov registry record · NA
Evaluation of Protein Loading on Measurement of Renal Reserve
A NA study, sponsored by MediBeacon.
- Not yet
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT07335614 is a NA study that has not yet begun recruiting, run by MediBeacon. The registered enrollment target is 25 participants.
The verdict
NCT07335614, a NA study, has not yet begun recruiting, sponsored by MediBeacon.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate the effect of protein loading on the measurement of renal reserve using the MediBeacon Transdermal glomerular filtration rate (tGFR) system. Adults with estimated glomerular filtration rate (eGFR) \>30 ml/min/1.73 m\^2 will be recruited to join the study. This is a potential new use for the tGFR for the assessment of renal reserve. Renal reserve is the increase in GFR that occurs in response to various stimuli, such as when one kidney is removed. The remaining kidney will often show an increase in GFR to compensate. Renal reserve is typically measured after a high protein meal and requires a reproducible stimulus and a repeated measurement of GFR. The main questions it aims to answer are: * To characterize the effect of protein loading on GFR (dose response curve) as assessed by the MediBeacon Transdermal GFR System * To determine Renal Reserve in participants with chronic kidney disease (CKD) using the MediBeacon Transdermal GFR System * To demonstrate whether any change in GFR following the protein stimulus is associated with a change in cardiac output using non-invasive bioimpedance (NICaS) Participants will participate in a Screening visit that will take place within 28 days of the scheduled administration of Lumitrace. On dosing day, participants will have the tGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon Transdermal GFR System initiated to collect background fluorescence. Following an injection of Lumitrace and the initiation of GFR assessments, participants will ingest a high protein meal over 15-20 minutes. They will be followed at the study center for up to 6-8 hours following administration of Lumitrace. All participants will participate in a follow-up phone call approximately 7 days after the last exposure to Lumitrace. Researchers will analyze the results to see if there is a detectable difference in fluorescence clearance rate following the high protein meal
Interventions
- DEVICE MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
- DEVICE Lumitrace
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-05 |
| Est. Completion | 2027-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07335614
The ClinicalTrials.gov registry entry for NCT07335614 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediBeacon, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) is the first listed.
NCT07335614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07335614 about?
NCT07335614 is a clinical study titled "Evaluation of Protein Loading on Measurement of Renal Reserve". The goal of this clinical trial is to evaluate the effect of protein loading on the measurement of renal reserve using the MediBeacon Transdermal glomerular filtration rate (tGFR) system. Adults with estimated glomerular filtration rate (eGFR) \>30 ml/min/1.73 m\^2 will be recruited to join the stud...
What is the current status of trial NCT07335614?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2026-05. Estimated completion is 2027-01.
What interventions are being tested in trial NCT07335614?
The interventions under investigation include: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) (DEVICE), Lumitrace (DEVICE).
Who is sponsoring clinical trial NCT07335614?
This trial is sponsored by MediBeacon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.